Cantor Fitzgerald Comments on BCAX FY2025 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Bicara Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings per share of ($2.50) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14).

A number of other analysts also recently commented on BCAX. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. HC Wainwright initiated coverage on Bicara Therapeutics in a report on Friday, December 6th. They set a “buy” rating and a $42.00 target price on the stock. Rodman & Renshaw assumed coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 price target for the company. Morgan Stanley assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective on the stock. Finally, TD Cowen started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Bicara Therapeutics has a consensus rating of “Buy” and an average target price of $43.00.

Bicara Therapeutics Stock Down 1.6 %

NASDAQ:BCAX opened at $11.73 on Thursday. Bicara Therapeutics has a 1 year low of $11.51 and a 1 year high of $28.09. The stock has a fifty day simple moving average of $17.46.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in Bicara Therapeutics in the fourth quarter worth approximately $147,000. Cinctive Capital Management LP bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at $229,000. Barclays PLC acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at $255,000. Jane Street Group LLC bought a new stake in Bicara Therapeutics in the third quarter worth $309,000. Finally, Teachers Retirement System of The State of Kentucky bought a new position in Bicara Therapeutics during the third quarter valued at about $358,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.